Comparing TriSalus Life Sciences (NASDAQ:TLSI) and Stagezero Life Sciences (OTCMKTS:SZLSF)

Stagezero Life Sciences (OTCMKTS:SZLSF) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Analyst Ratings

This is a summary of recent recommendations for Stagezero Life Sciences and TriSalus Life Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stagezero Life Sciences	0	0	0	0	0.00
TriSalus Life Sciences	1	1	3	0	2.40

TriSalus Life Sciences has a consensus price target of $11.00, suggesting a potential upside of 60.12%. Given TriSalus Life Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than Stagezero Life Sciences.

Earnings and Valuation

This table compares Stagezero Life Sciences and TriSalus Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stagezero Life Sciences	$3.80 million	0.02	-$11.41 million	($0.01)	-0.05
TriSalus Life Sciences	$29.43 million	11.66	-$30.05 million	($2.02)	-3.40

Stagezero Life Sciences has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Stagezero Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Stagezero Life Sciences has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Insider & Institutional Ownership

2.6% of TriSalus Life Sciences shares are owned by institutional investors. 2.5% of Stagezero Life Sciences shares are owned by company insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Stagezero Life Sciences and TriSalus Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stagezero Life Sciences	N/A	N/A	N/A
TriSalus Life Sciences	-98.45%	N/A	-111.88%

Summary

TriSalus Life Sciences beats Stagezero Life Sciences on 8 of the 13 factors compared between the two stocks.

About Stagezero Life Sciences

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.